Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 4 435 JPY 0.68% Market Closed
Market Cap: 127.7B JPY
Have any thoughts about
Torii Pharmaceutical Co Ltd?
Write Note

Torii Pharmaceutical Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Torii Pharmaceutical Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Torii Pharmaceutical Co Ltd
TSE:4551
Interest Income Expense
ÂĄ503m
CAGR 3-Years
N/A
CAGR 5-Years
22%
CAGR 10-Years
34%
Takeda Pharmaceutical Co Ltd
TSE:4502
Interest Income Expense
-ÂĄ175.7B
CAGR 3-Years
-15%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Interest Income Expense
ÂĄ24.3B
CAGR 3-Years
100%
CAGR 5-Years
60%
CAGR 10-Years
8%
Otsuka Holdings Co Ltd
TSE:4578
Interest Income Expense
ÂĄ20.5B
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
6%
Chugai Pharmaceutical Co Ltd
TSE:4519
Interest Income Expense
ÂĄ39m
CAGR 3-Years
-54%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Interest Income Expense
-ÂĄ7.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-7%
No Stocks Found

Torii Pharmaceutical Co Ltd
Glance View

Market Cap
124.7B JPY
Industry
Pharmaceuticals

Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Intrinsic Value
3 294.13 JPY
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Torii Pharmaceutical Co Ltd's Interest Income Expense?
Interest Income Expense
503m JPY

Based on the financial report for Sep 30, 2024, Torii Pharmaceutical Co Ltd's Interest Income Expense amounts to 503m JPY.

What is Torii Pharmaceutical Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
34%

Over the last year, the Interest Income Expense growth was 815%.

Back to Top